These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 16144928

  • 1. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
    Talpaz M, Rakhit A, Rittweger K, O'Brien S, Cortes J, Fettner S, Hooftman L, Kantarjian H.
    Clin Cancer Res; 2005 Sep 01; 11(17):6247-55. PubMed ID: 16144928
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma.
    Motzer RJ, Rakhit A, Thompson J, Gurney H, Selby P, Figlin R, Negrier S, Ernst S, Siebels M, Ginsberg M, Rittweger K, Hooftman L.
    Ann Oncol; 2002 Nov 01; 13(11):1799-805. PubMed ID: 12419754
    [Abstract] [Full Text] [Related]

  • 13. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
    Simonsson B, Gedde-Dahl T, Markevärn B, Remes K, Stentoft J, Almqvist A, Björeman M, Flogegård M, Koskenvesa P, Lindblom A, Malm C, Mustjoki S, Myhr-Eriksson K, Ohm L, Räsänen A, Sinisalo M, Själander A, Strömberg U, Bjerrum OW, Ehrencrona H, Gruber F, Kairisto V, Olsson K, Sandin F, Nagler A, Nielsen JL, Hjorth-Hansen H, Porkka K, Nordic CML Study Group.
    Blood; 2011 Sep 22; 118(12):3228-35. PubMed ID: 21685374
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
    Tóthová E, Fricová M, Kafková A, Stecová N, Guman T, Raffac S, Hlebasková M.
    Neoplasma; 2000 Sep 22; 47(2):125-8. PubMed ID: 10985480
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
    Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, Purdum PP, Jensen D, Smith C, Lee WM, Boyer TD, Lin A, Pedder S, DePamphilis J.
    Hepatology; 2001 Feb 22; 33(2):433-8. PubMed ID: 11172346
    [Abstract] [Full Text] [Related]

  • 20. Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia.
    Millot F, Brice P, Philippe N, Thyss A, Demeoq F, Wetterwald M, Boccara JF, Vilque JP, Guyotat D, Guilhot J, Guilhot F.
    J Pediatr Hematol Oncol; 2002 Jan 22; 24(1):18-22. PubMed ID: 11902732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.